tetano
Editor, Senior Moderator
Vaccine. 2017 Mar 9. pii: S0264-410X(17)30244-X. doi: 10.1016/j.vaccine.2017.02.041. [Epub ahead of print]
[h=1]Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus.[/h] Ui H[SUP]1[/SUP], Yamayoshi S[SUP]2[/SUP], Uraki R[SUP]2[/SUP], Kiso M[SUP]2[/SUP], Oishi K[SUP]2[/SUP], Murakami S[SUP]3[/SUP], Mimori S[SUP]4[/SUP], Kawaoka Y[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the first line of protection against influenza virus infection in humans. Although inactivated and live-attenuated vaccines are available, each vaccine has drawbacks in terms of immunogenicity and safety. To overcome these issues, our group has developed a replication-incompetent PB2-knockout (PB2-KO) influenza virus that replicates only in PB2-expressing cells. Here we generated PB2-KO viruses possessing the hemagglutinin (HA) and neuraminidase (NA) segments from H1N1pdm09 or type B viruses and tested their vaccine potential. The two PB2-KO viruses propagated efficiently in PB2-expressing cells, and expressed chimeric HA as expected. Virus-specific IgG and IgA antibodies were detected in mice immunized with the viruses, and the immunized mice showed milder clinical signs and/or lower virus replication levels in the respiratory tract upon virus challenge. Our results indicate that these PB2-KO viruses have potential as vaccine candidates.
Copyright ? 2017 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] PB2-KO virus; Replication-incompetent influenza virus
PMID: 28285982 DOI: 10.1016/j.vaccine.2017.02.041
[h=1]Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus.[/h] Ui H[SUP]1[/SUP], Yamayoshi S[SUP]2[/SUP], Uraki R[SUP]2[/SUP], Kiso M[SUP]2[/SUP], Oishi K[SUP]2[/SUP], Murakami S[SUP]3[/SUP], Mimori S[SUP]4[/SUP], Kawaoka Y[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the first line of protection against influenza virus infection in humans. Although inactivated and live-attenuated vaccines are available, each vaccine has drawbacks in terms of immunogenicity and safety. To overcome these issues, our group has developed a replication-incompetent PB2-knockout (PB2-KO) influenza virus that replicates only in PB2-expressing cells. Here we generated PB2-KO viruses possessing the hemagglutinin (HA) and neuraminidase (NA) segments from H1N1pdm09 or type B viruses and tested their vaccine potential. The two PB2-KO viruses propagated efficiently in PB2-expressing cells, and expressed chimeric HA as expected. Virus-specific IgG and IgA antibodies were detected in mice immunized with the viruses, and the immunized mice showed milder clinical signs and/or lower virus replication levels in the respiratory tract upon virus challenge. Our results indicate that these PB2-KO viruses have potential as vaccine candidates.
Copyright ? 2017 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] PB2-KO virus; Replication-incompetent influenza virus
PMID: 28285982 DOI: 10.1016/j.vaccine.2017.02.041